Ammonia toxicity to the brain: Effects on creatine metabolism and transport and protective roles of creatine

Molecular Genetics and Metabolism

Volumn 100, Issue SUPPL., 2010, Pages

  Braissant, Olivier ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Ammonia; Brain; Creatine; Hyperammonemia; Neuroprotection; Toxicity

Indexed keywords

AMMONIA; CARRIER PROTEIN; CREATINE; GLYCINE AMIDINOTRANSFERASE; GUANIDINOACETATE METHYLTRANSFERASE; PROTEIN SLC6A8; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ASTROCYTE; BRAIN ATROPHY; BRAIN CELL; BRAIN DAMAGE; BRAIN DEVELOPMENT; CONTROLLED STUDY; DEMYELINATION; EXPOSURE; GENE ACTIVITY; GENE EXPRESSION; GRAY MATTER; HYPERAMMONEMIA; METABOLISM; NERVE FIBER GROWTH; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; WHITE MATTER;

AMMONIA; ANIMALS; AXONS; BIOLOGICAL TRANSPORT; BRAIN; CELL CULTURE TECHNIQUES; CREATINE; HUMANS; MODELS, BIOLOGICAL; PROTECTIVE AGENTS;

EID: 77950339065     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.02.011     Document Type: Article

References (70)

1. Cagnon L., and Braissant O. Hyperammonemia-induced toxicity for the developing central nervous system. Brain Res. Rev. 56 (2007) 183-197
2. Flint Beal M., and Martin J.B. Major complications of cirrhosis. In: Fauci A.S., Braunwald E., Isselbacher K.J., Wilson J.D., Martin J.B., Kasper D.L., Hauser S.L., and Longo D.L. (Eds). Harrison's Principles of Internal Medicine (1998), McGraw-Hill, New York 2451-2457
3. Enns G.M. Neurologic damage and neurocognitive dysfunction in urea cycle disorders. Semin. Pediatr. Neurol. 15 (2008) 132-139
4. Tuchman M., Lee B., Lichter-Konecki U., Summar M.L., Yudkoff M., Cederbaum S.D., Kerr D.S., Diaz G.A., Seashore M.R., Lee H.S., McCarter R.J., Krischer J.P., and Batshaw M.L. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol. Genet. Metab. 94 (2008) 397-402
5. Gropman A.L., Summar M., and Leonard J.V. Neurological implications of urea cycle disorders. J. Inherit. Metab. Dis. 30 (2007) 865-879
6. Enns G.M., Berry S.A., Berry G.T., Rhead W.J., Brusilow S.W., and Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N. Engl. J. Med. 356 (2007) 2282-2292
7. Bachmann C. Mechanisms of hyperammonemia. Clin. Chem. Lab. Med. 40 (2002) 653-662
8. Bachmann C. Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation. Eur. J. Pediatr. 162 (2003) 410-416
9. Braissant O. Current concepts in the pathogenesis of urea cycle disorders. Mol. Gen. Metab. 100 (2010) S3-S12
10. Braissant O., Honegger P., Loup M., Iwase K., Takiguchi M., and Bachmann C. Hyperammonemia: regulation of argininosuccinate synthetase and argininosuccinate lyase genes in aggregating cell cultures of fetal rat brain. Neurosci. Lett. 266 (1999) 89-92
11. Bachmann C., Braissant O., Villard A.M., Boulat O., and Henry H. Ammonia toxicity to the brain and creatine. Mol. Genet. Metab. 81 Suppl. 1 (2004) S52-S57
12. Rao V.L.R. Nitric oxide in hepatic encephalopathy and hyperammonemia. Neurochem. Int. 41 (2002) 161-170
13. Scaglia F., Brunetti-Pierri N., Kleppe S., Marini J., Carter S., Garlick P., Jahoor F., O'Brien W., and Lee B. Clinical consequences of urea cycle enzyme deficiencies and potential links to arginine and nitric oxide metabolism. J. Nutr. 134 (2004) 2775S-2782S
14. Scaglia F., and Lee B. Clinical, biochemical, and molecular spectrum of hyperargininemia due to arginase I deficiency. Am. J. Med. Genet. C. Semin. Med. Genet. 142 (2006) 113-120
15. Leonard J.V., and Morris A.A. Urea cycle disorders. Semin. Neonatol. 7 (2002) 27-35
16. Braissant O., Henry H., Villard A.M., Zurich M.G., Loup M., Eilers B., Parlascino G., Matter E., Boulat O., Honegger P., and Bachmann C. Ammonium-induced impairment of axonal growth is prevented through glial creatine. J. Neurosci. 22 (2002) 9810-9820
17. Braissant O. Pathways depending on urea cycle intermediates. In: Bachmann C., Häberle J., Koch H.G., and Leonard J. (Eds). Pathophysiology and Management of Hyperammonemia (2007), SPS Publications, Heilbronn 25-41
18. Braissant O., Cagnon L., Monnet-Tschudi F., Speer O., Wallimann T., Honegger P., and Henry H. Ammonium alters creatine transport and synthesis in a 3D-culture of developing brain cells, resulting in secondary cerebral creatine deficiency. Eur. J. Neurosci. 27 (2008) 1673-1685
19. Choi C.G., and Yoo H.W. Localized proton MR spectroscopy in infants with urea cycle defect. AJNR Am. J. Neuroradiol. 22 (2001) 834-837
20. Klein A.M., and Ferrante R.J. The neuroprotective role of creatine. Subcell. Biochem. 46 (2007) 205-243
21. Braissant O., Henry H., Cagnon L., Honegger P., and Bachmann C. Glial mechanisms of axonal growth protection from ammonia. In: Häussinger D., Kircheis G., and Schliess F. (Eds). Hepatic Encephalopathy and Nitrogen Metabolism (2006), Springer, Dordrecht, Berlin, Heidelberg, New York 124-133
22. Wyss M., and Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol. Rev. 80 (2000) 1107-1213
23. Brosnan J.T., and Brosnan M.E. Creatine: endogenous metabolite, dietary, and therapeutic supplement. Annu. Rev. Nutr. 27 (2007) 241-261
24. Wallimann T., Tokarska-Schlattner M., Neumann D., Epand R.M., Epand R.F., Andres R.H., Widmer H.R., Hornemann T., Saks V.A., Agarkova I., and Schlattner U. The phosphocreatine circuit: molecular and cellular physiology of creatine kinases, sensitivity to free radicals and enhancement of creatine supplementation. In: Saks V.A. (Ed). Molecular Systems Bioenergetics: Energy for Life, Basic Principles, Organization and Dynamics of Cellular Energetics (2007), Wiley VCH-Publisher Co., Weinheim 195-264
25. Edison E.E., Brosnan M.E., Meyer C., and Brosnan J.T. Creatine synthesis: production of guanidinoacetate by the rat and human kidney in vivo. Am. J. Physiol. Renal. Physiol. 293 (2007) F1799-F1804
26. da Silva R.P., Nissim I., Brosnan M.E., and Brosnan J.T. Creatine synthesis: hepatic metabolism of guanidinoacetate and creatine in the rat in vitro and in vivo. Am. J. Physiol. Endocrinol. Metab. 296 (2009) E256-E261
27. Braissant O., Henry H., Loup M., Eilers B., and Bachmann C. Endogenous synthesis and transport of creatine in the rat brain: an in situ hybridization study. Mol. Brain Res. 86 (2001) 193-201
28. Braissant O., and Henry H. AGAT, GAMT and SLC6A8 distribution in the central nervous system, in relation to creatine deficiency syndromes: a review. J. Inher. Metab. Dis. 31 (2008) 230-239
29. Stöckler S., Schutz P.W., and Salomons G.S. Cerebral creatine deficiency syndromes: clinical aspects, treatment and pathophysiology. Subcell. Biochem. 46 (2007) 149-166
30. Van Pilsum J.F., Stephens G.C., and Taylor D. Distribution of creatine, guanidinoacetate and enzymes for their biosynthesis in the animal kingdom. Implications for phylogeny. Biochem. J. 126 (1972) 325-345
31. Pisano J.J., Abraham D., and Udenfriend S. Biosynthesis and disposition of γ-guanidinobutyric acid in mammalian tissues. Arch. Biochem. Biophys. 100 (1963) 323-329
32. Schmidt A., Marescau B., Boehm E.A., Renema W.K., Peco R., Das A., Steinfeld R., Chan S., Wallis J., Davidoff M., Ullrich K., Waldschutz R., Heerschap A., De Deyn P.P., Neubauer S., and Isbrandt D. Severely altered guanidino compound levels, disturbed body weight homeostasis and impaired fertility in a mouse model of guanidinoacetate N-methyltransferase (GAMT) deficiency. Hum. Mol. Genet. 13 (2004) 905-921
33. Tachikawa M., Fukaya M., Terasaki T., Ohtsuki S., and Watanabe M. Distinct cellular expressions of creatine synthetic enzyme GAMT and creatine kinases uCK-Mi and CK-B suggest a novel neuron-glial relationship for brain energy homeostasis. Eur. J. Neurosci. 20 (2004) 144-160
34. Nakashima T., Tomi M., Tachikawa M., Watanabe M., Terasaki T., and Hosoya K. Evidence for creatine biosynthesis in Müller glia. Glia 52 (2005) 47-52
35. Ohtsuki S., Tachikawa M., Takanaga H., Shimizu H., Watanabe M., Hosoya K., and Terasaki T. The blood-brain barrier creatine transporter is a major pathway for supplying creatine to the brain. J. Cereb. Blood Flow Metab. 22 (2002) 1327-1335
36. Nakashima T., Tomi M., Katayama K., Tachikawa M., Watanabe M., Terasaki T., and Hosoya K. Blood-to-retina transport of creatine via creatine transporter (CRT) at the rat inner blood-retinal barrier. J. Neurochem. 89 (2004) 1454-1461
37. Acosta M.L., Kalloniatis M., and Christie D.L. Creatine transporter localization in developing and adult retina: importance of creatine to retinal function. Am. J. Physiol. Cell Physiol. 289 (2005) C1015-C1023
38. Tachikawa M., Fujinawa J., Takahashi M., Kasai Y., Fukaya M., Sakai K., Yamazaki M., Tomi M., Watanabe M., Sakimura K., Terasaki T., and Hosoya K. Expression and possible role of creatine transporter in the brain and at the blood-cerebrospinal fluid barrier as a transporting protein of guanidinoacetate, an endogenous convulsant. J. Neurochem. 107 (2008) 768-778
39. Mak C.S., Waldvogel H.J., Dodd J.R., Gilbert R.T., Lowe M.T., Birch N.P., Faull R.L., and Christie D.L. Immunohistochemical localisation of the creatine transporter in the rat brain. Neuroscience 163 (2009) 571-585
40. Braissant O., Bachmann C., and Henry H. Expression and function of AGAT, GAMT and CT1 in the mammalian brain. Subcell. Biochem. 46 (2007) 67-81
41. Braissant O., Béard E., Torrent C., and Henry H. Dissociation of AGAT, GAMT and SLC6A8 in CNS: relevance to creatine deficiency syndromes. Neurobiol. Dis. 37 (2010) 423-433
42. Braissant O., Henry H., Villard A.M., Speer O., Wallimann T., and Bachmann C. Creatine synthesis and transport during rat embryogenesis: spatiotemporal expression of AGAT, GAMT and CT1. BMC Dev. Biol. 5 (2005) 9
43. Wang L., Zhang Y., Shao M., and Zhang H. Spatiotemporal expression of the creatine metabolism related genes AGAT, GAMT and CT1 during zebrafish embryogenesis. Int. J. Dev. Biol. 51 (2007) 247-253
44. Holtzman D., McFarland E., Moerland T., Koutcher J., Kushmerick M.J., and Neuringer L.J. Brain creatine phosphate and creatine kinase in mice fed an analogue of creatine. Brain Res. 483 (1989) 68-77
45. Hemmer W., Zanolla E., Furter-Graves E.M., Eppenberger H.M., and Wallimann T. Creatine kinase isoenzymes in chicken cerebellum: specific localization of brain-type creatine kinase in Bergmann glial cells and muscle-type creatine kinase in Purkinje neurons. Eur. J. Neurosci. 6 (1994) 538-549
46. 1H magnetic resonance spectroscopy. Magn. Reson. Med. 39 (1998) 28-33
47. De Deyn P.P., Marescau B., and Macdonald R.L. Guanidino compounds that are increased in hyperargininemia inhibit GABA and glycine responses on mouse neurons in cell culture. Epilepsy Res. 8 (1991) 134-141
48. Neu A., Neuhoff H., Trube G., Fehr S., Ullrich K., Roeper J., and Isbrandt D. Activation of GABA(A) receptors by guanidinoacetate: a novel pathophysiological mechanism. Neurobiol. Dis. 11 (2002) 298-307
49. De Deyn P.P., D'Hooge R., Van Bogaert P.P., and Marescau B. Endogenous guanidino compounds as uremic neurotoxins. Kidney Int. Suppl. 78 (2001) S77-S83
50. Cupello A., Balestrino M., Gatta E., Pellistri F., Siano S., and Robello M. Activation of cerebellar granule cells GABA(A) receptors by guanidinoacetate. Neuroscience 152 (2008) 65-69
51. Almeida L.S., Salomons G.S., Hogenboom F., Jakobs C., and Schoffelmeer A.N. Exocytotic release of creatine in rat brain. Synapse 60 (2006) 118-123
52. Bothwell J.H., Rae C., Dixon R.M., Styles P., and Bhakoo K.K. Hypo-osmotic swelling-activated release of organic osmolytes in brain slices: implications for brain oedema in vivo. J. Neurochem. 77 (2001) 1632-1640
53. Bothwell J.H., Styles P., and Bhakoo K.K. Swelling-activated taurine and creatine effluxes from rat cortical astrocytes are pharmacologically distinct. J. Membr. Biol. 185 (2002) 157-164
54. Bélanger M., Asashima T., Ohtsuki S., Yamaguchi H., Ito S., and Terasaki T. Hyperammonemia induces transport of taurine and creatine and suppresses claudin-12 gene expression in brain capillary endothelial cells in vitro. Neurochem. Int. 50 (2007) 95-101
55. Galbraith R.A., Furukawa M., and Li M. Possible role of creatine concentrations in the brain in regulating appetite and weight. Brain Res. 1101 (2006) 85-91
56. Honegger P., and Monnet-Tschudi F. Aggregating neural cell culture. In: Fedoroff S., and Richardson A. (Eds). Protocols for Neural Cell Culture (2001), Humana Press Inc., Totowa NJ 199-218
57. Bachmann C. Ornithine carbamoyl transferase deficiency: findings, models and problems. J. Inherit. Metab. Dis. 15 (1992) 578-591
58. Robinson M.B., Hopkins K., Batshaw M.L., McLaughlin B.A., Heyes M.P., and Oster-Granite M.L. Evidence of excitotoxicity in the brain of the ornithine carbamoyltransferase deficient sparse fur mouse. Brain Res. Dev. Brain Res. 90 (1995) 35-44
59. Hopkins K.J., McKean J., Mervis R.F., and Oster-Granite M.L. Dendritic alterations in cortical pyramidal cells in the sparse fur mouse. Brain Res. 797 (1998) 167-172
60. Felipo V., Grau E., Minana M.D., and Grisolia S. Activation of NMDA receptor mediates the toxicity of ammonia and the effects of ammonia on the microtubule-associated protein MAP-2. Adv. Exp. Med. Biol. 341 (1993) 83-93
61. Braissant O. Neurofilament proteins in brain diseases. In: Arlen R.K. (Ed). New Research on Neurofilament Proteins (2006), Nova Science Publishers Inc., New York 25-51
62. Brusilow S.W., and Horwich A.L. Urea cycles enzymes. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease (2001), McGraw-Hill, New York 1909-1963
63. Laursen H., and Diemer N.H. Morphometry of astrocyte and oligodendrocyte ultrastructure after portocaval anastomosis in the rat. Acta Neuropathol. 51 (1980) 65-70
64. Butterworth R.F. Effects of hyperammonaemia on brain function. J. Inher. Metab. Dis. 21 Suppl. 1 (1998) 6-20
65. Norenberg M.D., Rao K.V., and Jayakumar A.R. Mechanisms of ammonia-induced astrocyte swelling. Metab. Brain Dis. 20 (2005) 303-318
66. Perasso L., Cupello A., Lunardi G.L., Principato C., Gandolfo C., and Balestrino M. Kinetics of creatine in blood and brain after intraperitoneal injection in the rat. Brain Res. 974 (2003) 37-42
67. Schulze A., and Battini R. Pre-symptomatic treatment of creatine biosynthesis defects. Subcell. Biochem. 46 (2007) 167-181
68. Bender A., Koch W., Elstner M., Schombacher Y., Bender J., Moeschl M., Gekeler F., Müller-Myhsok B., Gasser T., Tatsch K., and Klopstock T. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 67 (2006) 1262-1264
69. Hersch S.M., Gevorkian S., Marder K., Moskowitz C., Feigin A., Cox M., Como P., Zimmerman C., Lin M., Zhang L., Ulug A.M., Beal M.F., Matson W., Bogdanov M., Ebbel E., Zaleta A., Kaneko Y., Jenkins B., Hevelone N., Zhang H., Yu H., Schoenfeld D., Ferrante R., and Rosas H.D. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 66 (2006) 250-252
70. Möller A., and Hamprecht B. Creatine transport in cultured cells of rat and mouse brain. J. Neurochem. 52 (1989) 544-550